Posted by Michael Wonder on 15 Jun 2017
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus
15 June 2017 - Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine.
Sandoz today announced that the US FDA has accepted its abbreviated new drug application for fluticasone propionate / salmeterol combination product, a substitutable generic version of Advair Diskus.
If approved, the product will treat asthma in patients aged four years and older, in addition to providing maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.
